NAPWHA calls on federal government to implement national access to HIV prevention drug
The national peak organisation for people with HIV, the National Association of People With HIV Australia (NAPWHA) calls on the federal government to urgently implement national access to a prevention drug for people at high risk of acquiring HIV.
Called Pre-Exposure Prophylaxis or PrEP, research has shown that HIV-negative partners of HIV-positive people who take the pill Truvada daily can reduce their risk of picking up HIV to virtually nil.
At a World AIDS Day event in Canberra on December 1, Health Minister the Hon Sussan Ley MP made encouraging comments regarding PrEP access incentives announced by state health departments, including the EPIC trial in New South Wales and new prescribing guidelines in Victoria.
“HIV is a national issue,” said Cipri Martinez, President of NAPWHA. “And NAPWHA is strongly advocating for PrEP to be made available Australia-wide.
"While its manufacturer Gilead has placed an application to the Therapeutic Goods Administration for approval, it will be at least mid-next year before there is a response.”
Without a PBS listing, people must pay up to $13,500 per year to access the drug for this purpose.
NAPWHA calls for national leadership to enable all Australians at risk of HIV to have equal access to PrEP until the PBS listing is finalised.
Read the full media release here.